Skip to main content

Advertisement

Table 8 Patient value conferred by drug classes across medicine [16, 37]

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Drug class Indication # of drugs Patient value gain (%)
Histamine H-1 receptor antagonists, oral Seasonal allergy 10 4–7
Histamine H-1 receptor antagonists, topical ocular Allergy, ocular 6 0.1–9.9
SSRI drugs Depression, major 5 20–23
Anti-depressants, non-SSRI Depression, major 6 21–32
cGMP-specific phosphodi-esterase inhibitors Erectile dysfunction 3 2.7–2.9
Proton pump inhibitors Acute erosive esophagitis 5 13–26
Proton pump inhibitors Gastroesophageal reflux 5 8–14
Proton pump inhibitors Zollinger-Ellison Syndrome 5 29–38
Histamine H-2 receptor antagonists Acute erosive esophagitis 4 5–11
Histamine H-2 receptor antagonists Gastroesophageal reflux 4 3–7
B-blockers, topical Glaucoma 3 16–19
Statins Hyperlipidemia 6 3–5
Diuretics Hypertension, systemic arterial 5 7.7–9.4
ACE inhibitors Hypertension, systemic arterial 9 6.5–9.1
B-blockers, oral Hypertension, systemic arterial 7 6.3–9.1
Hypnotics Insomnia 7 1.2–8.8
Ranibizumab, combined eye model Neovascular age-related macular degeneration, current study 1 16.3
Bisphosphonates Osteoporosis 3 0.8–1.1
α1-adrenergic blockers Prostatic hyperplasia 3 0.6–1.4
  1. All values are from the Center for Value-Based Medicine Pharmaceutical Value Index database©
  2. SSRI selective serotonin reuptake inhibitor, statins HMG-CoA reductase inhibitors